Gapping down
In reaction to earnings/guidance:
- HNI -2.7%, LII -2.4%, KMB -2.3%, CBU -2%
Other news:
- ERYP -28.8% (reports TRYbeCA-1 Phase 3 Trial of Eryaspase did not meet its primary endpoint of overall survival)
- PINS -14.3% (In response to market rumors regarding a potential acquisition of Pinterest by PayPal (PYPL), PayPal stated that it is not pursuing an acquisition of Pinterest at this time)
- FGEN -7.5% (announces analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2021)
- TPTX -2.1% (Presents Early Clinical Data for Repotrectinib)
- SBSW -2.1% (discloses entry into negotiations with affiliates of funds advised by Appian Capital Advisory LLP, regarding the acquisition of both the Santa Rita nickel and the Serrote copper mines, located in Brazil)
- ONDS -1.9% (files for 8,315,630 share common stock offering by selling shareholders)
- NVS -1.7% (reports top-line results for CANOPY-1 Phase III study did not meet its primary endpoints of overall survival)
Analyst comments:
- BV -2.3% (downgraded to Underweight from Neutral at JP Morgan)
- CCL -1.2% (downgraded to Neutral from Buy at Citigroup)